ГОР Анурадха (US),ВАРНЕР Кевин С. (US),ПУДЖАРА Четан П. (US),ГРЭХЭМ Ричард С. (US),ПАРАШАР Аджай П. (US),ЛИ Му-Лан (US),ДЖОРДАН Роберт С. (US),ЛИКИТЛЕРСУАНГ Сукхон (US)
申请号：
RU2014102492/15
公开号：
RU2014102492A
申请日:
2012.06.29
申请国别(地区):
RU
年份:
2015
代理人:
摘要：
1. A composition comprising an active pharmaceutical ingredient (API) and macrogol 15 gidroksistearat.2. A composition according to claim 1, characterized in that macrogol 15 hydroxystearate is contained in the API-solubilizing effective amount, wherein said amount is a concentration selected from the group consisting of about 0.1-50, 0.1-25, 0, 1-10 0.1-5, 0.1-1.0, 0.01-1.0, 0.01-0.1, 0.001-0.01, 0.1-2.0, 0, 2-2,0, 0.3-2.0, 0.4-2.0, 0.5-2.0, 0.6-2.0, 0,7-2,0, 0.8- 2.0, 0.9-2.0, 1.0-2.0, 1.1-2.0, 1.2-2.0, 1.3-2.0, 1.4-2, 0, 1.5-2.0, 1.6-2.0, 1.7-2.0, 1.8-2.0, 1.9-2.0, 0,1-1,9, 0,1-1,8, 0,1-1,7, 0.1-1.6, 0.1-1.5, 0,1-1,4, 0.1-1.3, 0, 1-1.2, 0.1-1.1, 0.1-1.0, 0.1-0.9, 0.1-0.8, 0.1-0.7, 0.1- 0.6, 0.1-0.5, 0.1-0.4, 0.1-0.3, 0.1-0.2, 0,2-1,9, 0.3-1, 8, 0.4-1.7, 0.5-1.6, 0.6-1.5, 0.7-1.4, 0.8-1.3, 0.9-1.2, 0.9-1.1, 0.1-3, 0.67, 0.01-5, 0.01-2, 1.0, 0.001-5, 0.001, 0.002, 0.003, 0.004, 0, 005, 0.006, 0.007, 0.008, 0.009, 0.01, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1.0, 1.1, 1.2, 1.3, 1, 4, 1.5, 1.6, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3.0, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3, 9, 4.0, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 6.0, 7.0, 8.0, 9.0, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 and 50% (wt. / wt. .3). A composition according to claim 1, characterized in that said active pharmaceutical ingredient is selected from the group consisting of cyclosporine, phentolamine, testosterone, testosterone derivative, simenepaga isopropyl, aganepaga isopropyl, compound 3, compound 4 and bimatoprosta.4. A composition according to claim 3, characterized in that said active pharmaceutical ingredient is selected from the group consisting of cyclosporin at a concentration of 0.001-0.1% (wt. / Wt.), In a concentration of phentolamine 0.001-1.0% (wt. / wt.) concentration of tes
